INCY compared with NBIX: revenue, margins and what each company keeps, and the suppliers and customers both name

INCYIncyte Corp

Mkt capRevenueRevenue

NBIXNeurocrine Biosciences Inc

Mkt capRevenueRevenue

Compare

INCYIncyte Corp

NBIXNeurocrine Biosciences Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

INCY

2 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±7.5%▼−0.06%×0.01

Q2 FY26±7.4%▲+9.30%×1.26

Q1 FY26±6.9%▲+2.12%×0.30

Feb 10 '26±6.2%▼−8.24%×1.32

NBIX

Reportimpliedrealized× implied

Q2 FY26—▼−10.08%—

Q1 FY26—▲+8.86%—

Feb 12 '26

= impliedINCY realized, solidNBIX realized, hatchedOne scale, both sides: full bar = 11%× = |realized| ÷ impliedSource: market data

—

▼−10.43%

—

Oct 29 '25—▼−6.35%—

INCYIncyte Corp

119.68▼−0.30%

Mkt cap$24.5BRevenue$1.6BQ3 FY26Revenue$5.1BFY25

NBIXNeurocrine Biosciences Inc

165.59▲+13.92%

Regular sessionNov 3 '26

Mkt cap$14.7BRevenue$1.1BQ3 FY26Revenue$2.9BFY25

Compare

Regular sessionNov 3 '26

INCYIncyte Corp

NBIXNeurocrine Biosciences Inc

119.68▼−0.30%

Price

165.59▲+13.92%

$24.5B

Mkt cap

$14.7B

Q3 FY26$1.6B

Revenue

$1.1BQ3 FY26

FY25$5.1B

Revenue

$2.9BFY25

INCY119.68▼−0.30%vsNBIX165.59▲+13.92%Regular sessionNov 3 '26